Cargando…
GOLPH3: a novel biomarker that correlates with poor survival and resistance to chemotherapy in breast cancer
The association between Golgi phosphoprotein 3 (GOLPH3) and clinical pathological characteristics, as well as the clinical outcomes of both neoadjuvant and adjuvant chemotherapies in breast cancer, remain largely unknown. In this study, we investigated the biological role and clinical significance o...
Autores principales: | Tang, Shicong, Pan, Hong, Wei, Wei, Yang, Huawei, Liu, Jianlun, Yang, Rirong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739628/ https://www.ncbi.nlm.nih.gov/pubmed/29285241 http://dx.doi.org/10.18632/oncotarget.21927 |
Ejemplares similares
-
Expression of GOLPH3 in patients with non-small cell lung cancer and xenografts models
por: Tang, Shicong, et al.
Publicado: (2018) -
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
por: Li, Si, et al.
Publicado: (2018) -
GOLPH3 and YB-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer
por: El-Maqsoud, Nehad M. R. Abd, et al.
Publicado: (2015) -
Clinical Efficacy of Including Capecitabine in Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Qiuyun, et al.
Publicado: (2013) -
High Expression of GOLPH3 in Esophageal Squamous Cell Carcinoma Correlates with Poor Prognosis
por: Wang, Jian-Hua, et al.
Publicado: (2012)